수탁제조 업계의 M&A : 함의와 전망(2023년판)

Abstract

This report is the fourth edition of our analysis of mergers and acquisitions in the pharmaceutical contract manufacturing industry. PharmSource is the most definitive, trustworthy source of strategic insight on this topic in the bio/pharmaceutical realm.

Scope

This 59-page report gives important, expert insight you won't find in any other source. 12 tables and 20 figures throughout the report illustrate major points and trends. This report is required reading for -

• CMOs: market trends, strategic planning, competitive intelligence, performance benchmarking
• Bio/Pharma: supplier performance benchmarking, market trends, competitive intelligence
• Private equity and stock analysts: target identification and analysis, portfolio company performance benchmarking

Reasons to Buy

• Overview of M&A in the Pharma CMO Industry
• Detailed view of CDMO performance by number of deals, based on GlobalData's Deals database
• Analysis of M&A and private equity investment by target's specific manufacturing services

Table of Contents

Table of Contents

• About GlobalData
• Executive Summary
• Players
• Technology Briefing
• Deal types
• Trends
• Industry Analysis
• Objectives and methodology
• Overview of M&A activity 2021-22
• Target characteristics
• Acquirer characteristics
• Geography
• Top acquirers
• Catalent's deal activity
• Recipharm's deal activity
• Segment close-ups of M&A activity, 2021-22
• Deal advisors
• Top financial advisors
• Top legal advisors
• Valuations
• Facility acquisitions
• What it means
• The outlook for M&A
• API-biologic targets
• API-cell and gene therapy targets
• Value Chain
• Companies

Appendix

• Methodology
• Bibliography
• Primary research - key opinion leaders
• Further reading
• About the Authors
• Contact Us